Diffuse large B-cell lymphoma (DLBCL) is one of the most common forms of non-Hodgkin lymphoma (NHL), accounting for approximately 30% of cases. The treatment landscape of DLBCL is evolving rapidly, particularly for patients with relapsed/refractory disease, with the recent addition of several new active agents to the armamentarium, and numerous other promising therapies in late-stage clinical development. Further, advances in understanding the underlying biology of DLBCL are resulting in more refined biomarker characterization for enhanced risk assessment and individualization of treatment. Clinicians must be aware of these changes and how to integrate them into their practices in order to optimize outcomes for their patients with DLBCL.

This program will utilize PER^®’s signature Medical Crossfire^® format to highlight current and emerging standards of care in DLBCL. Five expert faculty will present recent and emerging data from key clinical trials, and engage in discussions of how current and investigational agents are changing treatment paradigms in DLBCL, with an emphasis on practical strategies for integrating new therapies in the clinic. New therapeutic approaches and clinical trial options will also be discussed. Participants will have the opportunity to engage in a live question-and-answer session with the faculty, to clarify information and address challenging scenarios in their own clinics.